Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Integrative Single-cell And Bulk Rna Sequencing Identifies A Glycolysis-related Prognostic Signature For Predicting Prognosis In Pancreatic Cancer

Integrative Single-Cell and Bulk RNA Sequencing Identifies a Glycolysis-Related Prognostic Signature for Predicting Prognosis in Pancreatic Cancer

Nan Wu1,2, Chong Zhou1,2, Xu Yan1,2

  • 1Laboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.

International Journal of Molecular Sciences
|June 13, 2025

Related Experiment Videos

Single-cell RNA Sequencing and Analysis of Human Pancreatic Islets
11:34

Single-cell RNA Sequencing and Analysis of Human Pancreatic Islets

Published on: July 18, 2019

16.4K
Pancreatic Tissue Dissection to Isolate Viable Single Cells
08:04

Pancreatic Tissue Dissection to Isolate Viable Single Cells

Published on: May 26, 2023

2.5K
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.2K

View abstract on PubMed

Summary
This summary is machine-generated.

This study identifies key glycolysis genes, ENO1 and PGM2L1, that drive pancreatic adenocarcinoma (PAAD) progression. A new prognostic model using these genes accurately predicts patient survival and treatment response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Glycolysis alterations are critical in cancer, impacting pancreatic adenocarcinoma (PAAD) aggressiveness and treatment.
  • Specific glycolysis-related genes driving PAAD progression are not well understood.

Purpose of the Study:

  • To identify glycolysis-related genes and establish molecular subtypes in PAAD.
  • To develop a prognostic model for PAAD survival prediction.
  • To validate the role of identified genes in PAAD progression.

Main Methods:

  • Utilized TCGA datasets to define glycolysis-related molecular subtypes.
  • Developed and validated a glycolysis prognostic model.
  • Employed AUCell for neutrophil communication network analysis.
  • Performed in vitro and in vivo functional experiments to validate gene roles.
Keywords:
ENO1PGM2L1glycolysispancreatic adenocarcinoma

Related Experiment Videos

Single-cell RNA Sequencing and Analysis of Human Pancreatic Islets
11:34

Single-cell RNA Sequencing and Analysis of Human Pancreatic Islets

Published on: July 18, 2019

16.4K
Pancreatic Tissue Dissection to Isolate Viable Single Cells
08:04

Pancreatic Tissue Dissection to Isolate Viable Single Cells

Published on: May 26, 2023

2.5K
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.2K

Main Results:

  • Identified molecular subtypes with distinct survival outcomes, with favorable subtypes showing enhanced immune infiltration.
  • The glycolysis prognostic model accurately predicted PAAD survival and correlated with glycolytic pathways.
  • ENO1 and PGM2L1 co-expression promoted PAAD proliferation, migration, invasion, and tumor growth.
  • Knockdown of ENO1/PGM2L1 suppressed malignancy.

Conclusions:

  • A glycolysis prognostic risk model is a reliable tool for PAAD prognosis and progression prediction.
  • ENO1 and PGM2L1 are key risk factors promoting malignant progression in PAAD.
  • Understanding glycolysis pathways offers therapeutic targets for PAAD.
pancreatic cancer
risk model